Maraviroc (MVC) is a suitable drug for aviraemic subjects on antiretroviral treatment (ART) developing toxicity. Its prescription requires prior tropism testing. It is unknown if proviral DNA genotypic tropism testing is reliable for guiding MVC initiation in aviraemic subjects, so this study was carried out to address this issue.
Introduction
C-C chemokine receptor type 5 (CCR5) and C-X-C chemokine receptor type 4 (CXCR4) are the major cellular coreceptors involved in the entry of HIV-1 into the host cell. Based on the ability of the virus to use one or other of these co-receptors, HIV-1 variants are classified as R5-tropic, X4-tropic or dual tropic [1] . The development and approval of maraviroc (MVC), the first CCR5 antagonist to be used in a clinical context, which acts exclusively against R5 variants [2, 3] , has prompted the design of tools for rapid and easy determination of HIV co-receptor usage. The phenotypic assay Trofile â (Monogram BioSciences, San Francisco, CA, USA) has been the most widely used; however, it has logistical and technical limitations which have represented a serious obstacle for the widespread use of CCR5 antagonists in clinical settings, especially outside the USA, where the diagnostic company marketing the phenotypic test is located [4] . Several approaches based on V3 genotyping have been developed to predict HIV co-receptor usage over the last few years [5, 6] . It is encouraging that the clinical response to MVC has been reported to be similar when comparing different genotypic tools and the reference phenotypic Trofile â assay (Trofile and ES-Trofile) [7] [8] [9] [10] [11] .
As genotypic methods allow faster, easier and cheaper assessment of HIV tropism than phenotypic testing, their use has been replacing phenotypic tropism testing in most clinical settings, similar to what has happened with antiretroviral drug resistance testing over the same period. Indeed, various guidelines for HIV infection management, such as those published by GESIDA (http://www.ge sida.seimc.org) [12] , British (British HIV Association; http://bhiva.org/tropism-guidelines.aspx) [13] and European (http://www.europehivresistance.org) organizations [14] , specifically include within their recommendations the use of genotypic methods to guide the clinical use of CCR5 antagonists. Moreover, Spanish [15] and European [16] recommendations have been published to guide the use of CCR5 antagonists in clinical practice based on the genotypic determination of viral tropism. Special features of MVC such as its good safety profile, especially regarding metabolic parameters such as lipids and glucose, may allow consideration of its use as part of antiretroviral switch strategies [17] . In a context of low HIV RNA values or when RNA amplification from plasma samples is not successful, current Spanish [15] and European [16] recommendations to guide the use of CCR5 antagonists in clinical practice recommend the genotypic determination of HIV tropism from proviral DNA. The biological specimen should be complete blood from which DNA may be extracted directly or from peripheral blood mononuclear cells (PBMCs) obtained by conventional methods. However, scarce data exist about the reliability of these approaches to confidently guide the use of MVC in the clinic. To date, only retrospective analyses have evaluated the feasibility of HIV tropism determination from proviral DNA to guide the use of MVC in the clinical setting. A re-analysis of the Maraviroc versus Optimized Therapy in Viremic Antiretroviral Treatment-Experienced Patients (MOTIVATE)/A4001029 trials in antiretroviral-experienced patients [9] and some data obtained outside clinical trials in cohorts of patients in which MVC was initiated based on genotypic results suggest that HIV tropism determination from proviral DNA is a predictor of virological response to MVC, similar to determinations obtained using Trofile ™ and Enhanced Sensitivity Trofile Assay (ESTA) [17] [18] [19] [20] [21] [22] . In this context, the aim of this study was to prospectively validate the use of proviral DNA for HIV tropism determination to guide the use of CCR5 antagonists in patients on a suppressive antiretroviral therapy (ART) regimen switching to a regimen containing MVC plus two nucleoside reverse transcriptase inhibitors because of toxicity of current ART. Moreover, other parameters such as tolerance and safety after switching to MVC were evaluated at 24 and 48 weeks.
Materials and methods

Study population
PROTEST was a pilot, phase 4, prospective, single-arm clinical trial (ID: NCT01378910) carried out at 24 HIV care centres in Spain (see Appendix). MVC-na€ ıve, HIV-1-infected adult patients (≥ 18 years old) with HIV RNA < 50 copies/mL who had been on stable ART during the previous 6 months and who required an ART change because of toxicity and had no antiretroviral resistance to the ART started were selected. Subjects who met inclusion criteria and gave their informed consent to participate received a screening visit where a blood sample was collected for HIV tropism determination. Patients with R5 HIV initiated MVC in combination with two NRTIs and were followed at 4, 12, 24, 36 and 48 weeks. No changes in the NRTI backbone were allowed either at baseline or during the study follow-up. Virological failure was defined as two consecutive HIV RNA measurements > 50 copies/mL. Recent adherence was calculated as (pills taken/pills prescribed during the previous week) 9 100. The study was conducted following the principles expressed in the Declaration of Helsinki. All subjects provided written informed consent to participate. The study was reviewed and approved by the Institutional Review Boards of all the participating centres.
HIV-1 tropism determination
Tropism testing was centralized in four centres in Spain (irsiCaixa, Badalona; H San Cecilio Granada, Hospital Carlos III, and Instituto de Salud Carlos III, Madrid) using a standardized protocol [15] . Briefly, proviral DNA was extracted from PBMCs using conventional methods and the HIV-1 V3 envelope genomic region was amplified by singleton polymerase chain reaction (PCR) and sequenced, using conditions previously described [21, 23] . Genotypic prediction of viral tropism was carried out in all samples using geno2pheno [coreceptor] (http://www.geno2pheno.org) (clonal setting) with a false positive rate (FPR) of 10% (FPR-10%). Therefore, V3 sequences were classified as R5 variants when the V3 sequence displayed an FPR value ≤ 10%.
Statistical analysis
This was an estimation, single-arm, open-label clinical trial. The objective was to estimate the proportion of subjects remaining virologically suppressed (HIV-1 RNA < 50 copies/mL) 48 weeks after switching to MVC with a 6% precision. The initial sample size calculation to achieve this goal with a bilateral 95% confidence interval assuming that 85% of patients would remain suppressed after 48 weeks was 135 subjects being switched to MVC. When the study was originally designed, an 85% response rate was concordant with other studies assessing a treatment switch to other antiretrovirals under virological suppression. The population was described using standard descriptive statistics. Statistical significance in longitudinal changes in biochemical parameters was assessed using the Wilcoxon signed-rank test for paired samples.
Results
Screening flow chart
A total of 175 HIV-infected patients were selected at the screening phase. HIV tropism could be determined in 80.6% (n = 141) of patients screened. Of these, geno2-pheno FPR-10% classified 62% (n = 87) as R5 and 38% (n = 54) as X4. Finally, 85% (n = 74) of patients with R5 variants were included in the study for treatment switch to two NRTIs plus MVC (Fig. 1) . Reasons for not including subjects with R5 HIV were: withdrawal of consent to participate in the study (n = 7), physician decision after screening (n = 2), change of the protease inhibitor (PI) to a drug other than MVC (n = 1), change of the NRTI backbone (n = 1), protocol deviation (n = 1), and loss to follow-up as a result of a change of address. The median time interval between the tropism test and baseline was 28 days [interquartile range (IQR) 21, 42 days].
Baseline characteristics of the study population
Most patients were male (83.7%) and the median age was 48 years ( Table 1 ). The main risk groups for HIV transmission were men who have sex with men (MSM) (35%), injecting drug users (IDUs) (34%) and heterosexual (27%). Thirty-six per cent of the patients had Centers for Disease Control and Prevention (CDC) category C disease, and 62% and 10% were hepatitis C virus (HCV) and hepatitis B virus (HBV) coinfected, respectively. The median CD4 count was 616 cells/mL at screening and the median nadir CD4 count was 143 cells/lL. At baseline, 62% of subjects (n = 46) were on a PI-based regimen and 36% (n = 27) on a nonnucleoside reverse transcriptase inhibitor (NNRTI)-based regimen. Only one patient was undergoing integrase inhibitor (INI)-based therapy.
The main reasons for treatment switch to MVC were dyslipidaemia (42%), gastrointestinal symptoms (22%), liver toxicity (15%) and neuropsychiatric symptoms (11%). Other reasons were drugÀdrug interactions (1%) or porphyria (0.01%), with an additional 6.8% of patients being switched for reasons that were not defined. MVC was given alongside tenofovir/emtricitabine in 40 patients (54%), abacavir/lamivudine in 30 (40%), zidovudine/lamivudine in two (3%) and abacavir/tenofovir in two (3%). Clinical outcome after 48 weeks for patients switching to MVC plus two NRTIs based on proviral DNA genotypic determination Overall, 84% (62 of 74) of HIV-infected patients switching to MVC plus two NRTIs maintained HIV RNA levels < 50 copies/mL during the 48 weeks of follow-up. This figure had a final precision of 8.3%, which is a slightly lower precision than was originally planned (i.e. 6%). The remaining patients (n = 12) discontinued MVC-based therapy for the following reasons: two (3%) withdrew informed consent, one (1%) experienced an R5 to X4 tropic shift between the screening and baseline visits, one (1%) was lost to follow-up, one (1%) developed rash related to an ART adverse event, two (3%) died from non-study-related causes (myocardial infarction at week 1 in one case and lung cancer at week 36 in the other) and five (7%) developed protocol-defined virological failure. The main characteristics of patients who experienced a virological failure after switching to MVC are shown in Table 2 . Four patients presented with early virological failure (one patient at week 4 and the other three at week 12) and in the fifth patient virological failure was detected at week 36. Overall, HIV RNA values at the time of failure were low, ranging from 59 to 300 copies/mL, with the exception of one patient who failed with 14 102 copies/mL. In all cases, HIV-1 tropism was genotypically determined from plasma samples with the following results: two patients had samples classified as X4-tropic and two had samples classified as R5-tropic, and for one patient it was not possible to amplify the V3 loop. HIV drug resistance to NRTIs and PIs was evaluated in all patients at failure but results were obtained for only two of them. Patient 2 showed high-level resistance to emtricitabine (M184V) and intermediate-level resistance to tenofovir (M41L + T215Y + D67N), while patient 3 presented with high-level resistance to emtricitabine (M184V) but was fully susceptible to tenofovir. None of these patients had any evidence of HIV resistance before the study was started.
After failure, a rescue therapy without MVC was initiated for three of the five patients, two of them being the subjects who had experienced a shift to X4-tropic variants and the third being a subject who failed with R5-tropic virus but in whom resistance to lamivudine was detected. The remaining two patients continued with MVC plus tenofovir/emtricitabine. In all cases, patients achieved complete viral load suppression (HIV RNA < 50 copies/mL).
Regarding the lipid profile, a significant reduction in total cholesterol and triglycerides was observed at week 48 after switching to MVC-based therapy. Moreover, a significant reduction in the levels of both gamma-glutamyltranferase (GGT) and alkaline phosphatase (ALP) was observed (Fig. 2) . 
Discussion
Current HIV treatment guidelines recommend HIV tropism testing whenever the use of a CCR5 inhibitor is being considered [12] . In the last few years, the use of genotypic methods for HIV tropism determination has tended to replace the reference phenotypic assays (Trofile and ES-Trofile), especially in Europe. Indeed, several guidelines for HIV infection management specifically include within their recommendations the use of genotypic methods to guide the clinical use of CCR5 antagonists [12] [13] [14] . In patients on suppressive ART for whom a switch to MVC is planned for any reason (toxicity, drugÀdrug interactions, or simplification or intensification strategies), HIV tropism testing could be performed using proviral DNA [15, 16] . However, the data reported to date are scarce. A number of retrospective analyses have evaluated the feasibility of HIV tropism determination from proviral DNA to guide the use of MVC in the clinical setting [17] [18] [19] [20] [21] [22] . In a small pilot prospective randomized trial, switching the third drug to MVC was shown to be safe and efficacious and improved lipid parameters [24] . This phase 4 study prospectively evaluated the use of proviral DNA for HIV tropism determination to guide the use of CCR5 antagonists in 74 aviraemic HIV-infected patients who switched to the CCR5 antagonist MVC plus two NRTIs based on genotypic tropism testing of proviral HIV-1 DNA as a consequence of ART toxicity. After 48 weeks of follow-up, 84% of patients maintained HIV RNA levels of < 50 copies/mL. Precision around this figure was 8.3%, slightly lower than originally sought (i.e. 6%), given that final patient recruitment was also lower than was initially planned. This is the main limitation of the study, alongside the lack of a comparative control arm, making it necessary to consider our results in the context of other larger studies addressing this issue.
However, only five patients (6.7%) experienced protocol-defined virological failure after switching to MVC. They were mostly early failures (within the first 12 weeks) with low-level viraemia (HIV RNA < 300 copies/mL). In two of them, a shift from R5 to X4 variants and the development of drug resistance at reverse transcriptase (RT) and protease (PR) were detected. Two others, those who failed without RT or PR resistance mutations and no change in viral R5 tropism, continued MVC therapy and again achieved virological suppression. Therefore, these cases may represent transient viraemia "blips" rather than true virological failures. For the other three patients, salvage therapy based on darunavir/ritonavir or etravirine was initiated, with suppression of viraemia being achieved shortly thereafter.
The results obtained provide support for the use of the geno2pheno algorithm with an FPR of 10% in a singleton to determine HIV tropism from V3 sequences from proviral DNA. Several studies have attempted to determine which methodology determines HIV tropism most accurately and best predicts virological response to MVC [5, 6, [9] [10] [11] . At this time, geno2pheno is one of the most widely accepted and used algorithms for the interpretation of genotypic determination of HIV tropism. Initially, it was suggested that the use of triplicate population sequencing instead of a singleton, using geno2pheno with an FPR of 5.75%, might help to increase the test's sensitivity in detecting X4 variants that might preclude virological failure on MVC [26] . However, subsequent data demonstrated that using geno2pheno with an FPR of 10% yielded rates of virological responses to MVC that were comparable using either a single or three RT-PCRs [27] . In the case of HIV tropism determination from proviral DNA, there are several data from retrospective studies in cohorts of patients in whom MVC was initiated based on HIV tropism determination using geno2pheno with an FPR of 10% or 20%. In these studies, the rates of virological response to MVC were as high as 82% [16] [17] [18] . The results obtained in this prospective study suggest that an FPR of 10% is an accurate threshold for detecting X4-tropic variants, allowing rates of virological response of 84% in aviraemic patients switching to MVC plus two NRTIs after 48 weeks of follow-up.
The main reason for switching to MVC-based therapy in this study population was dyslipidaemia (42%). Overall, a significant reduction in total cholesterol and triglycerides was observed after 48 weeks of therapy with MVC plus two NRTIs. Changes were observed by treatment week 12 and levels remained stable thereafter. The magnitude of the effects observed was modest and may have been influenced by different overlapping factors, including different previous exposure to NNRTIs and PIs. However, these findings agree with those obtained in a post hoc analysis of the phase 3 Maraviroc versus Efavirenz in Treatment-naive Patients (MERIT) study in treatment-na€ ıve patients, which found that MVC was not associated with total cholesterol, low-density cholesterol or triglyceride elevations [18] . Moreover, a significant reduction in the levels of some hepatic enzymes was observed; this was the case for gamma-glutamyltransferase (GGT) and alkaline phosphatase (ALP). This favourable toxicity profile makes MVC an attractive drug for patients with cardiovascular risk and HBV and/or HCV coinfections as well as for patients with either nonalcoholic fatty liver disease (NAFLD) or steatohepatitis (NASH). Fig. 2 Evolution of analytical parameters after switching to maraviroc. *P < 0.05 relative to week 0. LDL, low-density lipoprotein; HDL, highdensity lipoprotein; AST, aspartate aminotransferase; GGT, gamma-glutamyl transpeptidase; ALP, alkaline phosphatase.
In summary, these results prospectively validate the use of genotypic tropism determination from proviral DNA (geno2pheno FPR 10%; singleton) in HIV-infected patients on suppressive ART in whom a switch to MVC is considered.
